Oxford Genetics is expecting a surge in revenue after securing six licensing deals for its gene therapy manufacturing technologies in the past 12 months. Oxford Genetics is a portfolio company of Mercia Technologies, which holds a 40.5 per cent direct equity stake in the business.

The business provides technology for drug and gene therapy development. Projects in the last year include a licence agreement with US service provider Aldevron and a collaboration with Sphere Fluidics to expedite the development of automated microfluidic systems.

Ryan Cawood, founder and chief executive of Oxford Genetics, said: “2018 was an outstanding year for our business and we are expecting to close our financial year to 30 April 2019 showing 300 per cent revenue growth on the prior year.

For further information and to read the full article, please click here



020 7071 3945


Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.